Prevalence of Grey Matter Pathology in Early Multiple Sclerosis Assessed by Magnetization Transfer Ratio Imaging

Overview of attention for article published in PLOS ONE, September 2011

Altmetric Badge

Mentioned by

news: 10 news outlets

Citations

dimensions_citation: 39 Dimensions

Readers on

mendeley: 63 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 10 news stories from 10 outlets.

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Pharmaceutical Daily, 11 Oct 2023

Late-breaking data from the DAYBREAK and RADIANCE trials show similarly low rates of progression independent relapse activity (PI…

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Stockwatch, 11 Oct 2023

Late-breakingdata from the DAYBREAK and RADIANCE trials show similarly low rates of progression independent relapse activity (PIR…

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

MarketScreener, 11 Oct 2023

Late-breaking data from the DAYBREAK and RADIANCE trials show similarly low rates of progression independent relapse activity (PI…

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Bakersfield, 11 Oct 2023

- Bristol Myers Squibb (NYSE: BMY) today announced new data showing that after eight years of follow-up, 76% of patients…

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Benzinga, 11 Oct 2023

Late-breaking data from the DAYBREAK and RADIANCE trials show similarly low rates of progression independent relapse activity (PI…

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Yahoo! Finance USA, 11 Oct 2023

Late-breaking data from the DAYBREAK and RADIANCE trials show similarly low rates of progression independent relapse activity (PI…

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Business Wire, 11 Oct 2023

Late-breaking data from the DAYBREAK and RADIANCE trials show similarly low rates of progression independent relapse activity (PI…

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Biospace, 11 Oct 2023

Late-breaking data from the DAYBREAK and RADIANCE trials show similarly low rates of progression independent relapse activity (PI…

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

PharmiWeb, 11 Oct 2023

Late-breaking data from the DAYBREAK and RADIANCE trials show similarly low rates of progression independent relapse activity (PI…

Understanding Physical and Cognitive Functioning in Patients With Relapsing Multiple Sclerosis

Neurology Live, 02 Oct 2023

For the estimated 2.3 million people worldwide living with relapsing forms of multiple sclerosis (RMS), cognitive impairment…

PLOS

Article Metrics

Prevalence of Grey Matter Pathology in Early Multiple Sclerosis Assessed by Magnetization Transfer Ratio Imaging

Mentioned by

Citations

Readers on

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Pharmaceutical Daily, 11 Oct 2023

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Stockwatch, 11 Oct 2023

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

MarketScreener, 11 Oct 2023

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Bakersfield, 11 Oct 2023

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Benzinga, 11 Oct 2023

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Yahoo! Finance USA, 11 Oct 2023

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Business Wire, 11 Oct 2023

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

Biospace, 11 Oct 2023

Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis

PharmiWeb, 11 Oct 2023

Understanding Physical and Cognitive Functioning in Patients With Relapsing Multiple Sclerosis

Neurology Live, 02 Oct 2023